ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2455

EP1 Receptor Antagonism Mitigates Early and Late-Stage Renal Fibrosis

Session Information

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms


  • Kresse, Jean-Claude, Aarhus Universitet, Aarhus, Midtjylland, Denmark
  • Mutsaers, Henricus A.M., Aarhus Universitet, Aarhus, Midtjylland, Denmark
  • Jensen, Michael Schou, Aarhus Universitet, Aarhus, Midtjylland, Denmark
  • Tingskov, Stine Julie Hyldal, Aarhus Universitet, Aarhus, Midtjylland, Denmark
  • Madsen, Mia Gebauer, Aarhus Universitetshospital, Aarhus, Denmark
  • Norregaard, Rikke, Aarhus Universitet, Aarhus, Midtjylland, Denmark

Renal fibrosis is a hallmark of Chronic Kidney Disease (CKD), which affects 10-16% of the world’s adult population. Yet current treatment strategies are ineffective in attenuating renal fibrogenesis. Therefore, we are in urgent need for new therapeutic strategies against renal fibrosis. The cyclooxygenase/prostaglandin (COX/PG) system plays a key role in renal fibrosis and holds great promise as a suitable therapeutic target. Here, we used a translational approach to evaluate the role of the PGE2-EP1 receptor in the pathogenesis of renal fibrosis in several models of kidney injury, including human (fibrotic) kidney slices.


The anti-fibrotic effect of SC-19220 - an EP1 receptor antagonist - was studied in Madin-Darby Canine Kidney (MDCK) cells, mice subjected to seven days of unilateral ureteral obstruction (UUO), and healthy and fibrotic human precision-cut kidney slices (PCKS). Progression of fibrosis was evaluated on gene and protein level using qPCR, Western blot and immunohistochemistry.


Pharmacological inhibition of the EP1 receptor using SC-19220 reduced TGF-β-induced fibronectin (FN) expression, ERK1/2 phosphorylation and epithelial-to-mesenchymal transition in MDCK cells. Moreover, SC-19220 diminished fibrosis in UUO mice, measured by decreased protein expression of FN and α-smooth muscle actin (αSMA), and a reduction in collagen deposition. In addition, treatment of healthy human PCKS with SC-19220 reduced TGF-β-induced fibrosis as shown by decreased gene levels of collagen 1A1, FN and αSMA as well as reduced collagen deposition. Moreover, similar observations were made using fibrotic human PCKS.


This study highlights that the EP1 receptor is a promising target for preventing both the onset and late stage of renal fibrosis. Moreover, we provide strong evidence that the effect of SC-19220 may translate to clinical care since its effects were observed in UUO mice and human kidney slices.